Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The patient with candidemia: Treatment choices and algorithms

The patient with candidemia: Treatment choices and algorithms Candidemia and other forms of invasive candidiasis have become increasingly important health care-associated infections. Risk factors are easily identified in patients with this disease, and about one half are residents of an ICU. In recent years, the treatment of candidemia and invasive candidiasis has significantly evolved from amphotericin B-based regimens to the echinocandins and fluconazole. A strategy of “step-down” therapy from an echinocandin to fluconazole in selected non-neutropenic patients with candidemia has been commonly practiced but not well studied. The approach to candidemia in the neutropenic patient is similar, but a lipid formulation of amphotericin B or voriconazole is often preferred because of the risk of concomitant mold infection. The biggest therapeutic challenge remaining to clinicians is the intensive care unit patient with multiple risk factors and a clinical suspicion of invasive candidiasis. Because optimal therapy in these patients is unknown, well-designed clinical trials and the continued development of non-culture-based diagnostic assays are crucial. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Fungal Infection Reports Springer Journals

The patient with candidemia: Treatment choices and algorithms

Current Fungal Infection Reports , Volume 2 (2) – May 30, 2008

Loading next page...
 
/lp/springer-journals/the-patient-with-candidemia-treatment-choices-and-algorithms-TEP0Vw6bNu

References (51)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Springer
Subject
Medicine & Public Health; Internal Medicine ; Infectious Diseases
ISSN
1936-3761
eISSN
1936-377X
DOI
10.1007/s12281-008-0017-z
Publisher site
See Article on Publisher Site

Abstract

Candidemia and other forms of invasive candidiasis have become increasingly important health care-associated infections. Risk factors are easily identified in patients with this disease, and about one half are residents of an ICU. In recent years, the treatment of candidemia and invasive candidiasis has significantly evolved from amphotericin B-based regimens to the echinocandins and fluconazole. A strategy of “step-down” therapy from an echinocandin to fluconazole in selected non-neutropenic patients with candidemia has been commonly practiced but not well studied. The approach to candidemia in the neutropenic patient is similar, but a lipid formulation of amphotericin B or voriconazole is often preferred because of the risk of concomitant mold infection. The biggest therapeutic challenge remaining to clinicians is the intensive care unit patient with multiple risk factors and a clinical suspicion of invasive candidiasis. Because optimal therapy in these patients is unknown, well-designed clinical trials and the continued development of non-culture-based diagnostic assays are crucial.

Journal

Current Fungal Infection ReportsSpringer Journals

Published: May 30, 2008

There are no references for this article.